title: Targeted drug delivery of Sunitinib Malate to tumor blood vessels by cRGD-chiotosan-gold nanoparticles.
abstract: The unique characteristics of tumor vasculature represent an attractive strategy for targeted delivery of antitumor and antiangiogenic agents to the tumor. The purpose of this study was to prepare c(RGDfK) labeled chitosan capped gold nanoparticles [cRGD(CS-Au) NPs] as a carrier for selective intracellular delivery of Sunitinib Malate (STB) to the tumor vasculature. cRGD(CS-Au) NPs was formed by electrostatic interaction between cationic CS and anionic AuNPs. cRGD modified CS-Au NPs had a spherical shape with a narrow size distribution. The entrapment efficiency of sunitinib molecule was found to be 45.2%±2.05. Confocal microscopy showed enhanced and selective uptake of cRGD(CS-Au) NPs into MCF-7 and HUVEC cells compared with non-targeted CS-Au NPs. Our results suggest that it may be possible to use cRGD(CS-Au) NPs as a carrier for delivery of anticancer drugs, genes and biomolecules for inhibiting tumor vasculature.
authors.affiliation: Nanotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Mohaddeseh Mahmoudi
authors.initials: MM
authors.lastname: Saber
authors.affiliation: Department of Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Sara
authors.initials: S
authors.lastname: Bahrainian
authors.affiliation: Nanotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran; Department of Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Rassoul
authors.initials: R
authors.lastname: Dinarvand
authors.affiliation: Nanotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran; Department of Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: atyabifa@tums.ac.ir.
authors.forename: Fatemeh
authors.initials: F
authors.lastname: Atyabi
mesh_terms: D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D048271:Chitosan / Q000737:chemistry; D004337:Drug Carriers / Q000737:chemistry*; D065546:Drug Liberation; D006046:Gold / Q000737:chemistry* / Q000493:pharmacokinetics; D006801:Humans; D007211:Indoles / Q000737:chemistry* / Q000493:pharmacokinetics*; D053758:Nanoparticles / Q000737:chemistry* / Q000648:ultrastructure; D009369:Neoplasms / Q000098:blood supply / Q000378:metabolism*; D010316:Particle Size; D010456:Peptides, Cyclic / Q000737:chemistry*; D011758:Pyrroles / Q000737:chemistry* / Q000493:pharmacokinetics*; D000077210:Sunitinib; D013499:Surface Properties
chemical_list: D004337:Drug Carriers; D007211:Indoles; D010456:Peptides, Cyclic; D011758:Pyrroles; C099250:cyclic (arginyl-glycyl-aspartyl-phenylalanyl-lysyl); C507169:cyclic arginine-glycine-aspartic acid peptide; D006046:Gold; D048271:Chitosan; D000077210:Sunitinib
keywords: Angiogenesis; Chitosan; Chitosan (PubChem CID: 71853); Cyclo(-RGDfK) (PubChem CID: 10196873); DAPI (PubChem CID: 2954); Dimethyl sulfoxide (PubChem CID: 679); Fluorescein isothiocyanate (PubChem CID: 18730); Formaldehyde (PubChem CID: 712); Gold nanoparticles; SPDP (PubChem CID: 157808); Sunitinib Malate; Sunitinib malate (PubChem CID: 6456015); Tetrachloroauric acid (PubChem CID: 10925836); Trisodium citrate (PubChem CID: 6224); c(RGD)